Glenmark Pharmaceuticals, USA (Glenmark) has received approval from the United States Food & Drug Administration (FDA) for Desonide cream, 0.05%, the generic version of Desonide cream, 0.05% of Perrigo New York.

According to IMS Health sales data for the 12 month period ending May 2017, the Desonide cream, 0.05% market achieved annual sales of approximately $44.6 million.

Glenmark’s current portfolio consists of 120 products authorized for distribution in the US marketplace and 65 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.